P

    PAVmed Inc (PAVM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.21
    +0.29 (+5.89%)

    Market Cap: $41.66M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +7.30%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.63 - $-0.63
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-4.20-566.7%
    60d ago$-4.20-566.7%
    30d ago$-0.69-9.5%
    7d ago$-0.69-9.5%
    Current$-0.63
    Revenue Consensus
    $50000
    Range$50000 - $50000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.67
    Range$-0.67 - $-0.67
    1 analysts
    Revenue Consensus
    $-7000
    Range$-7000 - $-7000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.67---
    Sep 26EST
    		-$-0.63---
    Jun 26
    Reported Aug 13
    		$-0.42$-0.66+36.36%Beat+72.0%
    Mar 26
    Reported May 15
    		$-1.17$-0.69-69.57%Miss-735.7%
    Dec 25
    Reported Mar 26
    		$-1.05N/A+76.67%Beat-452.6%
    Sep 25
    Reported Nov 13
    		$-0.60N/A+90.00%Beat+96.3%
    Jun 25
    Reported Aug 14
    		$-1.50N/A+80.00%Beat+75.0%
    Mar 25
    Reported May 15
    		$-0.14N/A+54.84%Beat+94.7%
    Dec 24
    Reported Mar 25
    		$-0.19N/A+52.50%Beat+99.6%
    Sep 24
    Reported Nov 13
    		$-16.20N/A+58.46%Beat+56.7%
    Jun 24
    Reported Aug 13
    		$-6.00N/A+85.07%Beat+87.1%
    Mar 24
    Reported May 13
    		$-2.62$-1.67-56.89%Miss+95.2%
    Dec 23
    Reported Mar 26
    		$-46.92$-53.70+12.63%Beat-20300.0%
    Sep 23
    Reported Nov 14
    		$-37.45$-63.00+40.56%Beat+44.5%
    Jun 23
    Reported Aug 15
    		$-46.41$-69.75+33.46%Beat+39.3%
    Mar 23
    Reported May 16
    		$-54.86$-74.25+26.11%Beat+12.9%
    Dec 22
    Reported Mar 14
    		$-0.23$-0.25+8.00%Beat-15.0%
    Sep 22
    Reported Nov 15
    		$-67.50$-105.75+36.17%Beat-50.0%
    Jun 22
    Reported Aug 16
    		$-76.50$-90.00+15.00%Beat-112.5%
    Mar 22
    Reported May 12
    		$-63.00$-85.50+26.32%Beat-75.0%
    Dec 21
    Reported Mar 29
    		$-0.20$-0.15-33.33%Miss-17.6%
    Sep 21
    Reported Nov 22
    		$-45.00$-42.75-5.26%Miss+0.0%
    Jun 21
    Reported Aug 12
    		$-36.00$-40.50+11.11%Beat+38.5%
    Mar 21
    Reported May 17
    		$-36.00$-40.50+11.11%Beat+75.8%
    Dec 20
    Reported Feb 22
    		$-0.17$-0.11-54.55%Miss+10.5%
    Sep 20
    Reported Nov 17
    		$-45.00$-49.50+9.09%Beat+0.0%
    Jun 20
    Reported Aug 18
    		$-58.50$-49.50-18.18%Miss+0.0%
    Mar 20
    Reported Apr 9
    		$-148.50$-49.50-200.00%Miss-153.8%
    Dec 19
    Reported Dec 31
    		$-0.19$-0.11-72.73%Miss-26.7%
    Sep 19
    Reported Nov 21
    		$-45.00$-45.00+0.00%Beat-20.2%
    Jun 19
    Reported Aug 14
    		$-58.50$-58.50+0.00%Beat-6.6%
    Mar 19
    Reported Apr 4
    		$-58.50$-58.50+0.00%Beat-292600.0%
    Dec 18
    Reported Mar 31
    		$-0.15$-0.14-7.14%Miss+99.8%
    Sep 18
    Reported Nov 15
    		$-37.44$-54.00+30.67%Beat-4.0%
    Jun 18
    Reported Aug 14
    		$-54.86$-49.50-10.83%Miss+12.9%
    Mar 18
    Reported May 21
    		$0.02$0.02+0.00%Beat+100.0%
    Sep 17
    Reported Nov 15
    		$-86.76$-63.00-37.71%Miss-37.7%
    Jun 17
    Reported Aug 14
    		$-36.00$-63.00+42.86%Beat-
    Mar 17
    Reported May 22
    		$-63.00$-63.00+0.00%Beat-
    Dec 16
    Reported Feb 16
    		$-58.50$-63.00+7.14%Beat-
    Sep 16
    Reported Nov 10
    		$-63.00$-67.50+6.67%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.61EV/EBITDA25.79x
    Price/FCF-4.20xFCF Yield-23.82%
    Profitability
    Profit Margin0.00%Operating Margin-21279.00%
    ROE-64.80%ROIC-20.53%
    Financial Health
    Debt/Equity0.43xInterest Coverage-3.79x
    Current Ratio1.19xQuick Ratio1.19x
    Trading Statistics
    Beta0.52Avg Volume46.55K
    52-Week High$17.9952-Week Low$3.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.14
    SMA 20$5.01
    SMA 50$5.20
    SMA 200$7.87
    EMA 10$5.11
    EMA 20$5.10
    EMA 50$5.36
    EMA 200$8.21

    MACD

    Line: -0.01Signal: -0.05Hist: 0.03

    ADX

    ADX: 12.1+DI: 18.1-DI: 18.0

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down48.0
    PSAR$4.63

    Bollinger Bands

    Upper Band$5.54
    Lower Band$4.47
    %B Position2152%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    51.6

    Momentum Oscillators

    Stoch %K62.2
    Stoch %D67.7
    Williams %R-27.7
    ROC (10d)-2.2%
    Momentum-0.12
    CCI (20d)30.0
    MFI (14d)42.0

    Volatility Measures

    ATR (14d)$0.42(8.0%)
    StdDev (20d)0.27
    Hist Vol86.9%(High)

    Volume Flow

    VWAP$5.11
    OBV49.3M
    AD Line40.8B
    CMF (20d)-0.064

    Volume Metrics

    Avg Vol (20d)48.5K
    Vol Ratio0.6x
    VWMA (20d)$4.66

    Pivot Points

    R3$5.30
    R2$5.23
    R1$5.07
    Pivot Point$5.00
    S1$4.84
    S2$4.77
    S3$4.61

    Advanced Oscillators

    TSI-1.03
    Ultimate Osc43.0
    KST-29.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$33,000$22,000$52,000$5,000$6,000$8,000$10,000$996,000$979,000$1.01M$1.05M$791,000
    Cost of Revenue$122,000$97,000$86,000$55,000$41,000$36,000$49,000$1.38M$1.67M$1.74M$1.61M$1.78M
    Gross Profit$-89,000$-75,000$-34,000$-50,000$-35,000$-28,000$-39,000$-385,000$-687,000$-734,000$-561,000$-988,000
    Operating Expenses$6.93M$7.96M$6.77M$4.79M$4.68M$5.42M$5.15M$11.19M$13.00M$13.30M$15.82M$14.54M
    R&D$2.07M$1.39M$1.83M$1.09M$790,000$787,000$808,000$1.54M$1.64M$1.94M$3.60M$3.16M
    SG&A$4.65M$6.36M$4.69M$3.50M$3.67M$4.38M$4.19M$6.65M$7.01M$6.68M$7.03M$6.86M
    Operating Income$-7,022,000$-8,035,000$-6,801,000$-4,844,000$-4,715,000$-5,446,000$-5,189,000$-11,578,000$-13,684,000$-14,036,000$-16,382,000$-15,528,000
    Interest Income$10,000$19,000$3,000$10,000$8,000$8,000$2,000$72.36M$110,000$72,000$97,000$124,000
    Interest Expense$2,000$3.42M$5,000$8,000$4,000$62,000$6,000$1.42M$774,000$2.38M$769,000$1.92M
    Income Before Tax$-6,598,000$-1,064,000$-2,757,000$-6,011,000$-12,324,000$18.62M$1.14M$60.71M$-14,914,000$-18,512,000$-17,407,000$-21,750,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,598,000$-1,064,000$-2,757,000$-6,011,000$-12,324,000$18.62M$1.14M$60.71M$-14,914,000$-18,512,000$-17,407,000$-21,750,000
    EBITDA$-6,587,000$2.36M$-2,737,000$-5,991,000$-12,306,000$18.72M$1.22M$-9,993,000$-13,945,000$-15,613,000$-16,010,000$-19,218,000
    EBIT$-6,606,000$2.34M$-2,755,000$-6,013,000$-12,328,000$18.68M$1.15M$-10,231,000$-14,250,000$-16,199,000$-16,735,000$-19,951,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PAVM

    News

    Form 8K PAVmed Inc For: 14 August By Investing.com

    This article from Investing.com announces an 8K filing by PAVmed Inc. for August 14. The brief piece includes the company's stock performance, showing a 9.70% increase, and is contextualized within general financial market data.

    Investing.com Nigeria•8/15/26•
    Neutral

    PAVmed (PAVM) Q2 2026 Earnings Call Transcript

    PAVmed (PAVM) held its Q2 2026 earnings call, reporting a GAAP net loss of $5.5 million and non-GAAP adjusted loss of $1.7 million. The company is making progress in commercialization and regulatory pathways across its Veris Health, Lucid Diagnostics, and medical device segments, including advancements for PortIO and Octeris. Management highlighted accelerating patient onboarding for Veris, expanding EsoGuard coverage, and the potential for a faster FDA 510(k) pathway for PortIO based on positive first-in-human study results.

    The Globe and Mail•8/15/26•
    Bullish

    PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing Losses and Strategic Progress Across VARIS, PortIO, and Lucid

    PAVmed Inc. reported significantly narrowed losses in Q2 2026, with a GAAP net loss of $6.6 million compared to $12.3 million in the prior year. The company is advancing the commercial launch of VARIS at Ohio State University, exploring a potentially faster 510(k) regulatory pathway for its PortIO device, and benefiting from expanded coverage policies for Lucid's EsoGuard. Despite increased R&D expenses and market volatility affecting Lucid's valuation, PAVmed's financial position improved through recent offerings, though its cash balance remains modest.

    GuruFocus•8/15/26•
    Neutral

    PAVM Q2 FY2026 earnings call

    PAVmed reported significantly narrowed losses in Q2 FY2026, with a GAAP net loss of $5.5 million compared to $12.3 million in the prior year, and a non-GAAP net loss of $1.7 million. The company highlighted progress across its portfolio, including expanded reimbursement for Lucid Diagnostics, accelerated commercial onboarding for Veris Health at Ohio State University, and positive first-in-human results for PortIO. PAVmed anticipates key catalysts such as a positive Medicare coverage decision for Lucid, potential 510(k) pathway for PortIO, and an early 2027 FDA submission for the Veris implantable device, with expected warrant proceeds providing liquidity.

    finance.biggo.com•8/14/26•
    Somewhat-Bullish

    Form 8K PAVmed Inc For: 14 August By Investing.com

    This article from Investing.com is a regulatory filing notification, specifically a Form 8K for PAVmed Inc. The brief content indicates that the filing was made on August 14th and the article itself was published on the same date. The article is very short and serves primarily as an alert for the filing.

    Investing.com India•8/14/26•
    Neutral

    Frequently Asked Questions About PAVM

    Does PAVM pay dividends?
    PAVmed Inc (PAVM) does not currently pay a regular dividend.
    What is PAVM's market cap?
    PAVmed Inc (PAVM) has a market capitalization of $41.66M with a current stock price of $5.21.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In